BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $52.50 Million Stake in iRhythm Technologies, Inc. (NASDAQ:IRTC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 38.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 707,175 shares of the company's stock after buying an additional 195,246 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 2.26% of iRhythm Technologies worth $52,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in IRTC. Segall Bryant & Hamill LLC lifted its position in shares of iRhythm Technologies by 2.1% in the third quarter. Segall Bryant & Hamill LLC now owns 132,602 shares of the company's stock worth $9,844,000 after buying an additional 2,742 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of iRhythm Technologies during the 3rd quarter worth $1,522,000. Oppenheimer Asset Management Inc. grew its stake in iRhythm Technologies by 17.3% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 9,275 shares of the company's stock valued at $689,000 after buying an additional 1,366 shares during the last quarter. Aigen Investment Management LP acquired a new stake in shares of iRhythm Technologies in the third quarter valued at about $243,000. Finally, State of New Jersey Common Pension Fund D boosted its stake in iRhythm Technologies by 32.5% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 28,414 shares of the company's stock valued at $2,109,000 after purchasing an additional 6,975 shares during the period.

iRhythm Technologies Price Performance

NASDAQ IRTC traded up $0.09 during trading hours on Friday, reaching $73.99. 420,161 shares of the company's stock were exchanged, compared to its average volume of 475,137. iRhythm Technologies, Inc. has a one year low of $55.92 and a one year high of $124.11. The firm has a fifty day moving average of $72.81 and a 200-day moving average of $82.45. The company has a current ratio of 6.27, a quick ratio of 6.12 and a debt-to-equity ratio of 9.00. The stock has a market cap of $2.32 billion, a PE ratio of -15.27 and a beta of 1.23.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.71). The firm had revenue of $147.54 million during the quarter, compared to analyst estimates of $146.69 million. iRhythm Technologies had a negative return on equity of 120.86% and a negative net margin of 26.90%. iRhythm Technologies's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.89) earnings per share. On average, equities research analysts predict that iRhythm Technologies, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at iRhythm Technologies

In other iRhythm Technologies news, CEO Quentin S. Blackford sold 16,145 shares of the company's stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $77.41, for a total value of $1,249,784.45. Following the completion of the sale, the chief executive officer now owns 159,929 shares of the company's stock, valued at approximately $12,380,103.89. This represents a 9.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Abhijit Y. Talwalkar purchased 6,664 shares of iRhythm Technologies stock in a transaction dated Monday, November 4th. The shares were purchased at an average cost of $75.16 per share, for a total transaction of $500,866.24. Following the completion of the transaction, the director now owns 18,941 shares of the company's stock, valued at approximately $1,423,605.56. This represents a 54.28 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.68% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IRTC shares. Robert W. Baird reduced their price objective on iRhythm Technologies from $100.00 to $79.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on shares of iRhythm Technologies from $133.00 to $100.00 and set an "overweight" rating for the company in a research report on Friday, August 2nd. Needham & Company LLC decreased their target price on iRhythm Technologies from $119.00 to $96.00 and set a "buy" rating on the stock in a research report on Thursday, October 31st. Citigroup cut their price target on iRhythm Technologies from $135.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, August 22nd. Finally, Oppenheimer decreased their price objective on iRhythm Technologies from $165.00 to $145.00 and set an "outperform" rating on the stock in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $108.50.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.